The oral LD50 of neomycin sulfate in mouse is > 8 g/kg. The subcutaneous LD50 is 200 mg/kg in rat and 190 mg/kg in mouse. The intraperitoneal LD50 in mouse is 305 mg/kg. The oral Lowest published toxic dose (TDLo) in woman is 12600 mg/kg/7D.L11982
Because of low absorption, acute overdosage from oral neomycin is not likely to occur. However, prolonged administration of neomycin should be avoided because of the possibility of some systemic absorption and the risk of neurotoxicity, ototoxicity, and/or nephrotoxicity. Hemodialysis will remove neomycin from the blood. While nephrotoxicity and ototoxicity have been reported in otherwise patients without compromised renal function, the risk for developing these toxicities is increased in patients with renal impairment.L11985 Like other aminoglycosides, neomycin may cause fetal harm and total irreversible bilateral congenital deafness when administered in pregnant women.L11979
Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of Streptomyces fradiae.L11979 Neomycin is a complex comprised of three components, neomycin A, B, and C.A191529 Neomycin B, also known as framycetin, is the most active component of the complex and neomycin C is the isomer of neomycin B, making these two stereoisomers the active components of neomycin.A175042,A191529 Neomycin A, or neamine, is a moiety that conjoins two molecules of neomycin B and C together.A175042 Neomycin is active against both gram-positive and gram-negative organisms and mediates its pharmacological action by binding to bacterial ribosomes and inhibiting protein synthesis, which is crucial for the survival of bacteria.L11985
Neomycin sulfate is the most common form for pharmaceutical preparations; because the compound is a complex, the amount of neomycin in products is measured in units.A191529 Neomycin sulfate as monotherapy is available in an oral solution for adjunct use in the treatment of hepatic coma.L11979 It is also used in combination with polymyxin B sulfates and hydrocortisone in otic suspensions for use in the treatment of bacterial infections in the external auditory canal, including infections caused by medical procedures in the ear.L10532 Neomycin is also used in combination with polymyxin B sulfates and dexamethasone in ophthalmic preparations for use in the treatment of inflammatory conditions and infections in the eye.L10716 Neomycin is also available in over-the-counter topical products to prevent minor skin infections.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Succinylcholine | The therapeutic efficacy of Succinylcholine can be increased when used in combination with Neomycin. |
| Metocurine iodide | The therapeutic efficacy of Metocurine iodide can be increased when used in combination with Neomycin. |
| Gallamine triethiodide | The therapeutic efficacy of Gallamine triethiodide can be increased when used in combination with Neomycin. |
| Cisatracurium | Neomycin may increase the neuromuscular blocking activities of Cisatracurium. |
| Rocuronium | The therapeutic efficacy of Rocuronium can be increased when used in combination with Neomycin. |
| Atracurium besylate | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Neomycin. |
| Doxacurium | The therapeutic efficacy of Doxacurium can be increased when used in combination with Neomycin. |
| Mivacurium | The therapeutic efficacy of Mivacurium can be increased when used in combination with Neomycin. |
| Decamethonium | The therapeutic efficacy of Decamethonium can be increased when used in combination with Neomycin. |
| Metocurine | The therapeutic efficacy of Metocurine can be increased when used in combination with Neomycin. |
| Pancuronium | The therapeutic efficacy of Pancuronium can be increased when used in combination with Neomycin. |
| Pipecuronium | The therapeutic efficacy of Pipecuronium can be increased when used in combination with Neomycin. |
| Vecuronium | The therapeutic efficacy of Vecuronium can be increased when used in combination with Neomycin. |
| Rapacuronium | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Neomycin. |
| Pyrantel | The therapeutic efficacy of Pyrantel can be increased when used in combination with Neomycin. |
| Neosaxitoxin | The therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Neomycin. |
| Atracurium | The therapeutic efficacy of Atracurium can be increased when used in combination with Neomycin. |
| Gallamine | The therapeutic efficacy of Gallamine can be increased when used in combination with Neomycin. |
| Alcuronium | The therapeutic efficacy of Alcuronium can be increased when used in combination with Neomycin. |
| Tubocurarine | The therapeutic efficacy of Tubocurarine can be increased when used in combination with Neomycin. |
| Acarbose | The metabolism of Acarbose can be decreased when combined with Neomycin. |
| Sorafenib | The serum concentration of Sorafenib can be decreased when it is combined with Neomycin. |
| Picosulfuric acid | The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Neomycin. |
| Zoledronic acid | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Neomycin is combined with Zoledronic acid. |
| Alendronic acid | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Neomycin is combined with Alendronic acid. |
| Ibandronate | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Neomycin is combined with Ibandronate. |
| Clodronic acid | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Neomycin is combined with Clodronic acid. |
| Risedronic acid | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Neomycin is combined with Risedronic acid. |
| Etidronic acid | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Neomycin is combined with Etidronic acid. |
| Incadronic acid | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Neomycin is combined with Incadronic acid. |
| Taxifolin | The risk or severity of nephrotoxicity can be increased when Taxifolin is combined with Neomycin. |
| Licofelone | The risk or severity of nephrotoxicity can be increased when Licofelone is combined with Neomycin. |
| Polmacoxib | The risk or severity of nephrotoxicity can be increased when Polmacoxib is combined with Neomycin. |
| Ebselen | The risk or severity of nephrotoxicity can be increased when Ebselen is combined with Neomycin. |
| Flurbiprofen axetil | The risk or severity of nephrotoxicity can be increased when Flurbiprofen axetil is combined with Neomycin. |
| Acetyldigitoxin | The risk or severity of adverse effects can be increased when Neomycin is combined with Acetyldigitoxin. |
| Deslanoside | The risk or severity of adverse effects can be increased when Neomycin is combined with Deslanoside. |
| Ouabain | The risk or severity of adverse effects can be increased when Neomycin is combined with Ouabain. |
| Digitoxin | The risk or severity of adverse effects can be increased when Neomycin is combined with Digitoxin. |
| Oleandrin | The risk or severity of adverse effects can be increased when Neomycin is combined with Oleandrin. |
| Cymarin | The risk or severity of adverse effects can be increased when Neomycin is combined with Cymarin. |
| Proscillaridin | The risk or severity of adverse effects can be increased when Neomycin is combined with Proscillaridin. |
| Lanatoside C | The risk or severity of adverse effects can be increased when Neomycin is combined with Lanatoside C. |
| Gitoformate | The risk or severity of adverse effects can be increased when Neomycin is combined with Gitoformate. |
| Peruvoside | The risk or severity of adverse effects can be increased when Neomycin is combined with Peruvoside. |
| Piretanide | The serum concentration of Neomycin can be increased when it is combined with Piretanide. |
| Azosemide | The serum concentration of Neomycin can be increased when it is combined with Azosemide. |
| Tripamide | The serum concentration of Neomycin can be increased when it is combined with Tripamide. |
| Flucloxacillin | The serum concentration of Neomycin can be decreased when it is combined with Flucloxacillin. |
| Dicloxacillin | The serum concentration of Neomycin can be decreased when it is combined with Dicloxacillin. |
| Carbenicillin | The serum concentration of Neomycin can be decreased when it is combined with Carbenicillin. |
| Nafcillin | The serum concentration of Neomycin can be decreased when it is combined with Nafcillin. |
| Hetacillin | The serum concentration of Neomycin can be decreased when it is combined with Hetacillin. |
| Benzylpenicilloyl polylysine | The serum concentration of Neomycin can be decreased when it is combined with Benzylpenicilloyl polylysine. |
| Mezlocillin | The serum concentration of Neomycin can be decreased when it is combined with Mezlocillin. |
| Cyclacillin | The serum concentration of Neomycin can be decreased when it is combined with Cyclacillin. |
| Benzylpenicillin | The serum concentration of Neomycin can be decreased when it is combined with Benzylpenicillin. |
| Azlocillin | The serum concentration of Neomycin can be decreased when it is combined with Azlocillin. |
| Cloxacillin | The serum concentration of Neomycin can be decreased when it is combined with Cloxacillin. |
| Amdinocillin | The serum concentration of Neomycin can be decreased when it is combined with Amdinocillin. |
| Bacampicillin | The serum concentration of Neomycin can be decreased when it is combined with Bacampicillin. |
| Meticillin | The serum concentration of Neomycin can be decreased when it is combined with Meticillin. |
| Pivampicillin | The serum concentration of Neomycin can be decreased when it is combined with Pivampicillin. |
| Pivmecillinam | The serum concentration of Neomycin can be decreased when it is combined with Pivmecillinam. |
| Ticarcillin | The serum concentration of Neomycin can be decreased when it is combined with Ticarcillin. |
| Azidocillin | The serum concentration of Neomycin can be decreased when it is combined with Azidocillin. |
| Carindacillin | The serum concentration of Neomycin can be decreased when it is combined with Carindacillin. |
| Sultamicillin | The serum concentration of Neomycin can be decreased when it is combined with Sultamicillin. |
| Temocillin | The serum concentration of Neomycin can be decreased when it is combined with Temocillin. |
| Epicillin | The serum concentration of Neomycin can be decreased when it is combined with Epicillin. |
| Pheneticillin | The serum concentration of Neomycin can be decreased when it is combined with Pheneticillin. |
| Carfecillin | The serum concentration of Neomycin can be decreased when it is combined with Carfecillin. |
| Propicillin | The serum concentration of Neomycin can be decreased when it is combined with Propicillin. |
| Clometocillin | The serum concentration of Neomycin can be decreased when it is combined with Clometocillin. |
| Sulbenicillin | The serum concentration of Neomycin can be decreased when it is combined with Sulbenicillin. |
| Penamecillin | The serum concentration of Neomycin can be decreased when it is combined with Penamecillin. |
| Talampicillin | The serum concentration of Neomycin can be decreased when it is combined with Talampicillin. |
| Aspoxicillin | The serum concentration of Neomycin can be decreased when it is combined with Aspoxicillin. |
| Metampicillin | The serum concentration of Neomycin can be decreased when it is combined with Metampicillin. |
| BCG vaccine | The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Neomycin. |
| Typhoid vaccine | The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Neomycin. |
| Lymecycline | The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Neomycin. |
| Clomocycline | The risk or severity of neuromuscular blockade can be increased when Clomocycline is combined with Neomycin. |
| Quinine | The risk or severity of neuromuscular blockade can be increased when Quinine is combined with Neomycin. |
| Tigecycline | The risk or severity of neuromuscular blockade can be increased when Tigecycline is combined with Neomycin. |
| Oxytetracycline | The risk or severity of neuromuscular blockade can be increased when Oxytetracycline is combined with Neomycin. |
| Demeclocycline | The risk or severity of neuromuscular blockade can be increased when Demeclocycline is combined with Neomycin. |
| Magnesium sulfate | The risk or severity of neuromuscular blockade can be increased when Magnesium sulfate is combined with Neomycin. |
| Metacycline | The risk or severity of neuromuscular blockade can be increased when Metacycline is combined with Neomycin. |
| Minocycline | The risk or severity of neuromuscular blockade can be increased when Neomycin is combined with Minocycline. |
| Clindamycin | The risk or severity of neuromuscular blockade can be increased when Neomycin is combined with Clindamycin. |
| Dantrolene | The risk or severity of neuromuscular blockade can be increased when Neomycin is combined with Dantrolene. |
| Rolitetracycline | The risk or severity of neuromuscular blockade can be increased when Neomycin is combined with Rolitetracycline. |
| Magnesium oxide | The risk or severity of neuromuscular blockade can be increased when Neomycin is combined with Magnesium oxide. |
| Magnesium cation | The risk or severity of neuromuscular blockade can be increased when Neomycin is combined with Magnesium cation. |
| Lincomycin | The risk or severity of neuromuscular blockade can be increased when Neomycin is combined with Lincomycin. |
| Viomycin | The risk or severity of neuromuscular blockade can be increased when Neomycin is combined with Viomycin. |
| Magnesium acetate tetrahydrate | The risk or severity of neuromuscular blockade can be increased when Neomycin is combined with Magnesium acetate tetrahydrate. |
| Magnesium citrate | The risk or severity of neuromuscular blockade can be increased when Neomycin is combined with Magnesium citrate. |
| Magnesium glycinate | The risk or severity of neuromuscular blockade can be increased when Neomycin is combined with Magnesium glycinate. |